

DAFTAR PUSTAKA

- Amann, R., Fuchs, B. M. (2008). Single-cell identification in microbial communities by improved fluorescence in situ hybridization techniques. *Nature Reviews Microbiology*. <https://doi.org/10.1038/nrmicro1888>
- Anand, N., Husain, N., Varshney, R., Malhotra, K. P., & Kaif, M. (2021). Molecular classification and stratification of adult diffuse gliomas: A tertiary care center study. *Journal of Carcinogenesis*, 20. https://doi.org/10.4103/jcar.jcar_17_21
- Aninditha T, Wiratman W. 2017. Buku ajar neurologi. Departemen Neurologi Fakultas Kedokteran Universitas Indonesia.
- Azad, A., Jackson, S., Cullinane, C., Natoli, A., Neilsen, P. M., Callen, D. F., ... & Solomon, B. (2011). Inhibition of DNA-Dependent Protein Kinase Induces Accelerated Senescence in Irradiated Human Cancer Cells DNA-PK Blockade and Radiation-Induced Senescence. *Molecular Cancer Research*, 9(12), 1696-1707. <https://doi.org/10.1158/1541-7786.MCR-11-0312>
- Babikir, H., Wang, L., Shamardani, K., Catalan, F., Sudhir, S., Aghi, M. K., ... & Diaz, A. A. (2021). ATRX regulates glial identity and the tumor microenvironment in IDH-mutant glioma. *Genome biology*, 22(1), 1-22. <https://doi.org/10.1186/s13059-021-02535-4>
- Berger, M.S., Hervey-Jumper, S., Wick, W., 2016. Astrocytic gliomas WHO grades II and III. *Handb Clin Neurol*. 2016;134:345-60. [doi: 10.1016/B978-0-12-802997-8.00021-9](https://doi.org/10.1016/B978-0-12-802997-8.00021-9).
- Bertram J. The Molecular Biology of Cancer. Honolulu: Molecular Aspect of Medicine; 2001
- Brennan, C. W., Verhaak, R. G., McKenna, A., Campos, B., Nounshmehr, H., Salama, S. R., ... & Davidsen, T. (2013). The somatic genomic landscape of glioblastoma. *Cell*, 155(2), 462-477. <https://doi.org/10.1016/j.cell.2013.09.034>.
- Bush, N. A. O., Chang, S. M., & Berger, M. S. (2017). Current and future strategies for treatment of glioma. *Neurosurgical review*, 40(1), 1-14. <https://doi.org/10.1007/s10143-016-0709-8>
- Butowski N, Chang S. Adult high grade glioma. Dalam: Barnett GH. High grade glioma. Edisi ke-1. New Jersey: Humana Press; 2007. h. 59-69.
- Cai, J., Zhang, C., Zhang, W., Wang, G., Yao, K., Wang, Z., ... & Jiang, C. (2016). ATRX, IDH1-R132H and Ki-67 immunohistochemistry as a classification scheme for astrocytic tumors. *Oncoscience*, 3(7-8), 258. <https://doi.org/10.18632/oncoscience.317>
- Cai, J., Yang, P., Zhang, C., et al. 2014. ATRX mRNA expression combined with IDH1/2 mutational status and Ki-67 expression refines the molecular classification of astrocytic tumors: evidence from the whole transcriptome

sequencing of 169 samples. www.impactjournals.com/oncotarget/ Oncotarget, Vol. 5, No. 9

Chang et al., Treatment of Adult Lower Grade Glioma in the Era of Genomic Medicine. ASCO.org/ edbook. 2016

Chatterjee, D., Radotra, B.D., Kumar, N., Vasishta, K., Gupta, S. K. 2018. IDH1, ATRX, and BRAFV600E mutation in astrocytic tumors and their significance in patient outcome in north Indian population. *Surgical Neurology International* 2018, 9:29 <http://www.surgicalneurologyint.com/content/9/1/29>.

Chaurasia, A., Park, S.H., et al. (2016). Immunohistochemical Analysis of ATRX, IDH1 and p53 in Glioblastoma and Their Correlations with Patient Survival. *J Korean Med Sci* 2016; 31: 1208-1214. <http://dx.doi.org/10.3346/jkms.2016.31.8.1208>

Chen, R., Smith-Cohn, M., Cohen, A. L., & Colman, H. (2017). Glioma subclassifications and their clinical significance. *Neurotherapeutics*, 14(2), 284-297. *Neurotherapeutics*.[https:// doi: 10.1007/s13311-017-0519-x](https://doi.org/10.1007/s13311-017-0519-x)

Clark, O., Yen, K., & Mellinghoff, I. K. (2016). Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer Isocitrate Dehydrogenase Mutations in Cancer. *Clinical Cancer Research*, 22(8), 1837-1842.[https:// doi: 10.1158/1078-0432.CCR-13-1333](https://doi.org/10.1158/1078-0432.CCR-13-1333).

Cohen, A. L., Holmen, S. L., & Colman, H. (2013). IDH1 and IDH2 mutations in gliomas. *Current neurology and neuroscience reports*, 13(5), 1-7. [https:// doi: 10.1007/s11910-013-0345-4](https://doi.org/10.1007/s11910-013-0345-4)

Coons SW, Johnson PC, Scheithauer BW, et al.. (1997). Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. *Cancer*. [https:// doi: 10.1002/\(sici\)1097-0142\(19970401\)79:7<1381::aid-cnrcr16>3.0.co;2-w](https://doi.org/10.1002/(sici)1097-0142(19970401)79:7<1381::aid-cnrcr16>3.0.co;2-w)

Cree IA, Lokuhety D, Peteroen LAN, et al.. WHO Classification of Tumors of the Central Nervous System. World Health Organization Classification of Tumours. Lyon: International Agency for Research on Cancer; 2021.

Dang, L., Yen, K., & Attar, E. C. (2016). IDH mutations in cancer and progress toward development of targeted therapeutics. *Annals of Oncology*, 27(4), 599-608. [https:// doi: 10.1093/annonc/mdw013](https://doi.org/10.1093/annonc/mdw013)

Davis, M. E. (2018, December). Epidemiology and overview of gliomas. In *Seminars in oncology nursing* (Vol. 34, No. 5, pp. 420-429). [https:// doi: 10.1016/j.soncn.2018.10.001](https://doi.org/10.1016/j.soncn.2018.10.001)

Dietrich J. Clinical presentation, initial surgical approach, and prognosis of high grade glioma. UpToDate [serial online]. 2018 [diunduh 14 Februari 2018]. Tersedia: UpToDate.

Diwanji, T. P., Engelman, A., Snider, J. W., & Mohindra, P. (2017). Epidemiology,

diagnosis, and optimal management of glioma in adolescents and young adults. *Adolescent health, medicine and therapeutics*, 8, 99. <https://doi.org/10.2147/AHMT.S53391>

Dong, X., Noorbakhsh, A., Hirshman, B.R., et al. 2016. Survival trends of grade I, II, and III astrocytoma patients and associated clinical practice patterns between 1999 and 2010: A SEER-based analysis. *Neuro-Oncology Practice* 3(1), 29–38, 2016. doi:10.1093/nop/npv016

Eckel-Passow, J. E., Lachance, D. H., Molinaro, A. M., Walsh, K. M., Decker, P. A., Sicotte, H., ... & Jenkins, R. B. (2015). Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. *New England Journal of Medicine*, 372(26), 2499-2508. <https://doi.org/10.1056/NEJMoa1407279>

Fernandes C, Costa A, Osorio L, Lago R, Linhares P, Carvalho B, et al. 2018. Current standards of care in glioblastoma therapy. Dalam: De-Vleeschouwer S. Editor. Glioblastoma (serial online). Brisbane: Codon Publications; 2018: edisi 1, tersedia dari front matter.

Grech, N., Dalli, T., Mizzi, S., Meilak, L., Calleja, N., & Zrinzo, A. (2020). Rising incidence of glioblastoma multiforme in a well-defined population. *Cureus*, 12(5). <https://doi.org/10.7759/cureus.8195>

Han, CH., Batchelor, TT. (2017). Isocitrate dehydrogenase mutation as a therapeutic target in gliomas. *Chin Clin Oncol* 2017; 6: 33.

Hanahan, D., Weinberg, R. (2011). Hallmarks of Cancer: The Next Generation. DOI 10.1016/j.cell.2011.02.013

Hanif Farina, Muzaffar Kanza, Perveen Kahkashan, Malhi M Saima, Simjee U. Glioblastoma Multiforme: A review of its epidemiology and pathogenesis through clinical presentation and treatment. *Asian Pac J Cancer Prev*. 2017;18(1):3-9.

Ho, V. K., Reijneveld, J. C., Enting, R. H., Bienfait, H. P., Robe, P., Baumert, B. G., & Visser, O. (2014). Changing incidence and improved survival of gliomas. *European journal of cancer*, 50(13), 2309-2318. <https://doi.org/10.1016/j.ejca.2014.05.019>

Hofer, S., Rushing, E., Preusser, M., & Marosi, C. (2014). Molecular biology of high-grade gliomas: what should the clinician know?. *Chinese journal of cancer*, 33(1), 4. <https://doi.org/10.5732/cjc.013.10218>

Hu, C., Wang, K., Damon, C., Fu, Y., Ma, T., Kratz, L., ... & Li, Y. (2022). ATRX loss promotes immunosuppressive mechanisms in IDH1 mutant glioma. *Neuro-oncology*, 24(6), 888-900. <https://doi.org/10.1093/neuonc/noab292>

Hu, W.M., Wang, F., Xi, S.Y., Zhang, X., Lai, J.P. 2020. Practice of the New Integrated Molecular Diagnostics in Gliomas: Experiences and New Findings in a Single Chinese Center. *Journal of Cancer* 2020; 11(6): 1371-1382. doi: 10.7150/jca.38603

- Ikemura, M., Shibahara, J., Mukasa, A., Takayanagi, S., Aihara, K., Saito, N., ... & Fukayama, M. (2016). Utility of ATRX immunohistochemistry in diagnosis of adult diffuse gliomas. *Histopathology*, 69(2), 260-267. <https://doi.org/10.1111/his.12927>
- Jalal, J. A., Rowandizy, A. I. S., & Ismael, A. T. (2020). Immunohistochemical expression of ATRX in gliomas. *Cellular and Molecular Biology*, 66(7), 131-135. <http://dx.doi.org/10.14715/cmb/2020.66.7.20>
- James D. Molecular genetics of tumors of the central nervous system: brain tumor. contemporary cancer research. Humana Press; 2005.
- Jha P, Shukla S, Vagha S. (2021). Correlation of IDH1-(R132H) and ATRX Expression with the Histopathological Grades of Glial Tumours: A Study Protocol. *Journal of Pharmaceutical Research International*. [https://doi: 10.9734/jpri/2021/v33i64B35420](https://doi.org/10.9734/jpri/2021/v33i64B35420)
- Jiao, Y., Killela, P.J., Reitman, Z., et al. 2012. Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. www.impactjournals.com/oncotarget. *Oncotarget* 2012; 3: 709-722.
- Johnson Derek R, Jaeckle KA. Low grade glioma and oligodendroma in adulthood. Neuro-oncology. Edisi ke-1. New Jersey: Blackwell Publishing Ltd; 2012; h 76-85.
- Jiang, H., Cui, Y., Wang, J., & Lin, S. (2017). Impact of epidemiological characteristics of supratentorial gliomas in adults brought about by the 2016 world health organization classification of tumors of the central nervous system. *Oncotarget*, 8(12), 20354. [https://doi: 10.18632/oncotarget.13555](https://doi.org/10.18632/oncotarget.13555)
- Kalkanis SN, Rosenblum ML. Malignant glioma. Dalam: Ogden AT, Bruce JN. Pineal region tumors. Dalam: Bernstein M, Berger MS. Neuro-oncology the essentials. Edisi ke-2. New York: Thieme; 2008. h. 254-65.
- Kannan, K., Inagaki, A., Silber, J., Gorovets, D., Zhang, J., Kastenhuber, E. R., ... & Huse, J. T. (2012). Whole exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma. *Oncotarget*, 3(10), 1194. [https://doi: 10.18632/oncotarget.689](https://doi.org/10.18632/oncotarget.689).
- Mayank, K. Vikas, G. (2022). Astrocytoma, Continuing Education Activity <https://www.ncbi.nlm.nih.gov/books/NBK559042>.
- Karsy, M., Guan, J., Cohen, A. L., Jensen, R. L., & Colman, H. (2017). New molecular considerations for glioma: IDH, ATRX, BRAF, TERT, H3 K27M. *Current neurology and neuroscience reports*, 17(2), 1-13. [https://doi: 10.1007/s11910-017-0722-5](https://doi.org/10.1007/s11910-017-0722-5)
- Komori, T. (2020). Updating the grading criteria for adult diffuse gliomas: beyond the WHO 2016 CNS classification. *Brain Tumor Pathology* (2020) 37:1–4

<https://doi.org/10.1007/s10014-020-00358-y>

- Komori, T. (2022). Grading of adult diffuse gliomas according to the 2021 WHO Classification of Tumors of the Central Nervous System. *Laboratory Investigation*, 102(2), 126-133.. <https://doi.org/10.1007/s10014-022-00428-3>
- Koschmann, C., Calinescu, A. A., Nunez, F. J., Mackay, A., Fazal-Salom, J., Thomas, D., ... & Castro, M. G. (2016). ATRX loss promotes tumor growth and impairs nonhomologous end joining DNA repair in glioma. *Science translational medicine*, 8(328), 328ra28-328ra28. <https://doi.org/10.1126/scitranslmed.aac8228>
- Kumar V, Abbas A, Aster J. Robbins and Cotran pathologic basis of disease. Edisi ke-9. Philadelphia (Pa.): Elsevier Saunders; 2015.
- Lee EQ, Wen PY. Cancer neurology. In Samuels MA & Ropper AH, Samuels's Manual of Neurologic Therapeutics ninth edition. Wolters Kluiver; 2017.
- Liu, J., Zhang, X., Yan, X., Sun, M. E. I., Fan, Y., & Huang, Y. (2019). Significance of TERT and ATRX mutations in glioma. *Oncology letters*, 17(1), 95-102. <https://doi.org/10.3892/ol.2018.9634>
- Louis D, Ohgaki H, Wiestler O, Cavenee W, Burger P, Jouvet A, et al. 2007. The 2007 WHO classification of tumours of the central nervous system. *Acta Neuropathol*. 2007;114(2):97-109.
- Louis D. N, Ohgaki H, Wiestler OD, et al.. (2016). *WHO Classification of Tumors of the Central Nervous System*. (Vol. 4th revised). Lyon: International Agency for Research on Cancer.
- Louis D, Perry A, Reifenberger G, Von-Deimling A, Figarella-Branger D, Cavenee W, et al. 2016. World Health Organization classification of tumors of the central nervous system: a summary. *Acta Neuropathol*. 2016;131(6):803-20.
- Louis, D. N., Wesseling, P., Aldape, K., Brat, D. J., Capper, D., Cree, I. A., ... & Ellison, D. W. (2020). cIMPACT NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT Utrecht meeting on future CNS tumor classification and grading. *Brain Pathol*. <https://doi.org/10.1111/bpa.12832>.
- Lovejoy, C. A., Li, W., Reisenweber, S., Thongthip, S., Bruno, J., De Lange, T., ... & ALT Starr Cancer Consortium. (2012). Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway. *PLoS genetics*, 8(7), e1002772. <https://doi.org/10.1371/journal.pgen.1002772>
- Lu, Richard Q., Qian, L., Zhou, X. (2019). Developmental origins and oncogenic pathways in malignant brain tumors. [wires.wiley.com/devbio](https://www.wireless.wiley.com/devbio). <https://doi.org/10.1002/wdev.342>
- Lu, V. M., O'Connor, K. P., Shah, A. H., Eichberg, D. G., Luther, E. M., Komotar, R. J., & Ivan, M. E. (2020). The prognostic significance of CDKN2A

homozygous deletion in IDH-mutant lower-grade glioma and glioblastoma: a systematic review of the contemporary literature. *Journal of neuro-oncology*, 148(2), 221-229. [https:// doi: 10.1007/s11060-020-03528-2](https://doi.org/10.1007/s11060-020-03528-2)

Manjunath, N., Jha, P., Singh, J., Raheja, A., Kaur, K., Suri, A., & Suri, V. (2021). Clinico-pathological and molecular characterization of diffuse midline gliomas: is there a prognostic significance?. *Neurological Sciences*, 42(3), 925-934. <https://doi.org/10.1007/s10072-020-04489-0>

Malueka, R.G., Dwianingsih, E. K., et al. (2020). Clinicopathological Features and Prognosis of Indonesian Patients with Gliomas with IDH Mutation: Insights into Its Significance in a Southeast Asian Population. *Asian Pac J Cancer Prev*, 21 (8), 2287-2295. [https:// doi: 10.31557/APJCP.2020.21.8.2287](https://doi.org/10.31557/APJCP.2020.21.8.2287)

Mesfin FB, Al-Dhahir MA.(2022). Gliomas. Treasure Island (FL): *StatPearls*.

Miller, J. J., Shih, H. A., Andronesi, O. C., & Cahill, D. P. (2017). Isocitrate dehydrogenase mutant glioma: evolving clinical and therapeutic implications. *Cancer*, 123(23), 4535-4546. [https://doi:10.1002/cncr.31039](https://doi.org/10.1002/cncr.31039)

Molinaro, A. M., Taylor, J. W., Wiencke, J. K., & Wrensch, M. R. (2019). Genetic and molecular epidemiology of adult diffuse glioma. *Nature Reviews Neurology*, 15(7), 405-417. [https:// doi: 10.1038/s41582-019-0220-2](https://doi.org/10.1038/s41582-019-0220-2)

Nandakumar, P., Mansouri, A., & Das, S. (2017). The role of ATRX in glioma biology. *Frontiers in oncology*, 7, 236. [https:// doi: 10.3389/fonc.2017.00236](https://doi.org/10.3389/fonc.2017.00236).

Narayan Vairavan, Patel Krunal, Price Stephen. High grades Gliomas: Pathogenesis, Management and Prognosis. *Neurosurgery*. 2012;

National Comprehensive Cancer Network. Central Nervous System Cancers. 2018.

Negrini, S., Gorgoulis, V. G., & Halazonetis, T. D. (2010). Genomic instability— an evolving hallmark of cancer. *Nature reviews Molecular cell biology*, 11(3), 220-228. [https:// doi: 10.1038/nrm2858](https://doi.org/10.1038/nrm2858).

Noverón NR, Mohar-Betancourt A, Ortiz-Rafael J. Epidemiology of Brain Tumors. *Principles of Neuro-Oncology*, 15-25. [https://doi: 10.1007/978-3-030- 54879-7_2](https://doi.org/10.1007/978-3-030-54879-7_2)

Ostrom, Q. T., Gittleman, H., Stetson, L., Virk, S., & Barnholtz-Sloan, J. S. (2018). Epidemiology of intracranial gliomas. *Intracranial Gliomas Part I-Surgery*, 30, 1-11. [https:// doi: 10.1159/000464374](https://doi.org/10.1159/000464374)

Ostrom Q, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, dkk. CBTRUS statistical report primary brain and central nervous system tumors diagnosed in the United States in 2008-2012 *Neurooncol*. 2015;17(suppl 4): iv1-62.

Panduan Penatalaksanaan Tumor Otak. 2016. (pp. 8-9). Jakarta: Kementrian Kesehatan Indonesia

- Park S, Won J, Kim S, Lee Y, Park C, Kim S, et. Al. 2017. Molecular testing of brain tumor. *J Pathol Transl Med*. 2017;51(3):205-23.
- Peeters, M., Dirven, L., Koekkoek, J. A., Gortmaker, E. G., Fritz, L., Vos, M. J., & Taphoorn, M. J. (2020). Prediagnostic symptoms and signs of adult glioma: the patients' view. *Journal of Neuro-Oncology*, 146(2), 293-301. [https:// doi: 10.1007/s11060-019-03373-y](https://doi.org/10.1007/s11060-019-03373-y).
- Perez, A., & Huse, J. T. (2021). The Evolving Classification of Diffuse Gliomas: World Health Organization Updates for 2021. *Current neurology and neuroscience reports*, 21(12), 1-10. [https:// doi: 10.1007/s11910-021-01153-8](https://doi.org/10.1007/s11910-021-01153-8)
- Perry, A. 2003. Pathology of low grade gliomas: An update of emergin concepts. *Neuro-oncology* 5:168-178
- Persaud-Sharma, D., Burns, J., Trangle, J., Moulik, S. (2017). Disparities in Brain Cancer in the United States: A Literature Review of Gliomas. *Med. Sci*. 2017, 5, 16; [doi:10.3390/medsci5030016](https://doi.org/10.3390/medsci5030016)
- Purkait, S., Miller, C. A., Kumar, A., Sharma, V., Pathak, P., Jha, P., & Sarkar, C.(2017). ATRX in diffuse gliomas with its mosaic/heterogeneous expression in a subset. *Brain Pathology*, 27(2), 138-145. <https://doi.org/10.1111/bpa.12364>
- Raynaud S, Carbuccion N, Colin C, et al (2010). Absence of R140Q mutation of isocitrate dehydrogenase 2 in gliomas and breast cancers. *Oncol Lett*, 1,883-4.
- Recht L.D, Vogel H, Harsh G.R, Blue books of neurology: Low grade Astrocytomas. 2012. p:121-129
- Reuss, D. E., Sahm, F., Schrimpf, D., Wiestler, B., Capper, D., Koelsche, C., & von Deimling, A. (2015). ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an “integrated” diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. *Acta neuropathologica*, 129(1), 133-146. [https:// doi 10.1007/s00401-014-1370-3](https://doi.org/10.1007/s00401-014-1370-3)
- Rodriguez, F., Cashman, J.A.B, Allen, S.J., et al. 2018. Alternative lengthening of telomeres, ATRX loss and H3-K27M mutations in histologically defined pilocytic astrocytoma with anaplasia. *Brain Pathology* ISSN 1015-6305.[doi:10.1111/bpa.12646](https://doi.org/10.1111/bpa.12646)
- Sarma, S., Khonglah, Y., Mishra, J., Kakati, A., & Phukan, P. (2021). Gliomas-An experience based on molecular markers. *Journal of Family Medicine and Primary Care*, 10(3), 1341. [https:// doi: 10.4103/jfmpe.jfmpe_1963_20](https://doi.org/10.4103/jfmpe.jfmpe_1963_20)scitranslmed.aac8228
- Schneider T, Mawrin C, Scherlach C, Skalej M, Firsching R. Gliomas in adults. *Dts Arztebl Int*. 2010;107(45):799-08.

- Schoenfeld DA. Sample-size formula for the proportional-hazards regression model. *Biometrics* 1983;39:499-503.
- Singh, S., Deora, H., Neyaz, A., Das, K. K., Mehrotra, A., Srivastava, A. K., & Jaiswal, S. (2021). Trends in clinico-epidemiology profile of surgically operated glioma patients in a tertiary care center over 12 years—through the looking glass!. *Egyptian Journal of Neurosurgery*, 36(1), 1-8. <https://doi.org/10.1186/s41984-021-00118-w>
- Soffietti et al., Guidelines on the management of low-grade gliomas: EANO task force report. *European Association of NeuroOncology Magazine*. 2011; www.kup.at/journals/eano/index.html
- Shofty B, Bokstein F, Ram Z, Ben-Sira L, Freedman S, Kesler A, Constantini S. Low grade gliomas. *Neuro Oncol*. 2014;16(supl 1):i60-i70.
- Stockhammer F, Misch M, Helms HJ, et al. IDH1/2 mutations in WHO grade II astrocytomas associated with localization and seizure as the initial symptom. *Seizure*. 2012; 21:194-197. [PubMed: 22217666]
- Takano, S., Ishikawa, E., Sakamoto, N., Matsuda, M., Akutsu, H., Noguchi, M., & Matsumura, A. (2016). Immunohistochemistry on IDH 1/2, ATRX, p53 and Ki-67 substitute molecular genetic testing and predict patient prognosis in grade III adult diffuse gliomas. *Brain tumor pathology*, 33(2), 107-116. [https:// doi: 10.1007/s10014-016-0260-x](https://doi.org/10.1007/s10014-016-0260-x)
- Tamimi, A. F., & Juweid, M. (2017). Epidemiology and outcome of glioblastoma. *Exon Publications*, 143-153. [https:// doi:10.15586/codon.glioblastoma.2017.ch8](https://doi.org/10.15586/codon.glioblastoma.2017.ch8)
- Tove L, Hansson H, Stein S, Sverre H. 2012. Prognostic value of histological features in diffuse astrocytoma WHO grade II. *International J Clin Experimental Pathol*. 2012;5(2):152-8.
- Trupti, T., Kinjal, P., Neha, B., Charmi, J., Priti, T., Harsha, P., Nikhil, M. 2020. Co-occurrence of ATRX and IDH Mutations Identify Subgroup of Glioma Patients for Better Survival. *Gujarat Cancer Society Research Journal*. Volume 22 Number 2 October 2020
- Turcotte-Cardin, V., Young, K. G., & Picketts, D. J. (2019). ATRX tames repetitive DNA within heterochromatin to promote normal brain development and regulate oncogenesis. In *Chromatin Signaling and Neurological Disorders* (pp. 235-257). *Academic Press*. <https://doi.org/10.1016/B978-0-12-813796-3.00011-0>
- Uiju, C., Seung, H., et al. (2021). Estimation of the occurrence rates of IDH1 and IDH2 mutations in gliomas and the reconsideration of IDH-wildtype anaplastic astrocytomas: an institutional experience. *Journal of International Medical Research* 49(6) 1–11. DOI: 10.1177/03000605211019258. journals.sagepub.com/home/imr

- Uno M, Oba-Shinjo SM, Silva R, et al (2011). IDH1 mutations in a Brazilian series of glioblastoma. *Clinics*, 66, 163-5.
- Valle-Folgueral J, Mascarenhas L, Costa J, Viera F, Soares-Fernandes J, Beleza P, et al. 2008. Giant cellglioblastoma: review of the literature and illustrated case. *Neurocirugica (Astur)*. 2008;19(4):343-9.
- Van den Bent MJ, Dubbink HJ, Marie Y, et al (2010). IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. *Clin Cancer Res*, 16, 1597-604.
- Veduruvada, R.L., Uppin, M.S., Konatam, M.L., Alugolu, R. et al. 2021. Clinical, Morphological, and Molecular Study of Diffuse WHO Grade II and III Astrocytomas: A Retrospective Analysis from a Single Tertiary Care Institute. *Ind J Med Paediatr Oncol* 2021;42:569–576. DOI <https://doi.org/10.1055/s-0041-1741061>. ISSN 0971-5851.
- Vigneswaran K, Neill S, Hadjipanayis C. 2015. Beyond the world health organization grading of infiltrating gliomas: advances in the molecular genetics of glioma classification. *Ann Transl Med*. 2015;3(7):95.
- Wang, HY., Tang, K., Liang, TY., et al. (2016). The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas. *J Exp Clin Cancer Res* 2016; 35: 86.
- Weller M, Van-Den-Bent M, Hopkins K, Tonn J, Stupp R, Falini A, et al. 2014. EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma . *Lancet Oncol*. 2014;15(9):e395-e403.
- Wen et al. Updated Response Assessment Criteria for High grade Glioma: Response Assessment in Neuro-Oncology Working Group. *Journal of Clinical Oncology*. Vol.28. No.11. 2010
- Wiestler, B., Capper, D., Holland, T., Korshunov, A., et al. 2013. ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. *Acta Neuropathol* DOI 10.1007/s00401-013-1156-z
- Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., & Bigner, D. (2009). IDH1 and IDH2 mutations in gliomas. *New England journal of medicine*, 360(8), 765-773. [https:// doi: 10.1056/NEJMoa0808710](https://doi.org/10.1056/NEJMoa0808710).
- Zhao S, Lin Y, Xu W, Jiang W, Zha Z, Wang P, Yu W, Li Z, Gong L, Peng Y, Ding J, Lei Q, Guan KL, et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. *Science*. 2009; 324:261–265.